Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Takashi Hisai"'
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Publikováno v:
Liver Cancer (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, th
Externí odkaz:
https://doaj.org/article/48f623fe69374965a18cf38cb68f57fa
Autor:
Yuxian Bai, Xichun Hu, Zhenggang Ren, Takashi Hisai, Wataru Yusa, Lidong Weng, Sari Shiba, Takao Takase
Publikováno v:
Future Oncology. 18:2413-2424
Aim: This phase I study assessed the pharmacokinetic profile, safety and antitumor activity of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma. Materials & methods: Bodyweight-based lenvatinib dosing was administered (patien
Autor:
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Makiko Ono, Tetsuya Urasaki, Akihiro Ohmoto, Tsubasa Kawanai, Takashi Hisai, Hiroki Ikezawa, Sari Shiba, Ken Ito, Taro Semba, Osamu Asano, Shunji Takahashi
Publikováno v:
Cancer.
Autor:
Takeyuki Iwata, Masahiro Kobayashi, Hiroki Ikezawa, Corina E. Dutcus, Hiromitsu Kumada, Mayumi Suzuki, Masafumi Ikeda, Kenta Motomura, Takuji Okusaka, Naoya Kato, Masatoshi Kudo, Takashi Hisai
Publikováno v:
Journal of Clinical Oncology. 38:513-513
513 Background: LEN, a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT with immunomodulatory activity, is approved in multiple countries for first-line treatment of uHCC. NIV is an anti-PD-1 monoclonal antibody approved in mul
Autor:
Masatoshi Kudo, Kiwamu Okita, Takashi Hisai, Takuya Suzuki, Seiji Kawazoe, Hiromitsu Kumada, Kenji Ikeda, Seiichi Hayato, Takuji Okusaka, Yukio Osaki, Masafumi Ikeda, Toshiyuki Tamai
Publikováno v:
Journal of Gastroenterology
Background Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter st
Publikováno v:
Thin Solid Films. 500:278-282
Extramembranous and peripheral light-harvesting complexes (chlorosomes) of green sulfur photosynthetic bacterium Chlorobium tepidum were electrostatically immobilized on a pyrex glass plate with the help of cationic polylysines. Absorbance of both So
Autor:
Takuji Okusaka, Yukio Osaki, Hiromitsu Kumada, Kenji Ikeda, Toshiyuki Tamai, Masafumi Ikeda, Hideaki Miyagishi, Takashi Hisai, Kiwamu Okita, Takuya Suzuki, Masatoshi Kudo
Publikováno v:
Journal of Clinical Oncology. 35:309-309
309 Background: Lenvatinib is an oral tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. A phase 1/2 trial in pts (n = 46) with advanced HCC and Child-Pugh score A treated with lenvatinib 12 mg once daily showed a median overall s